Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 150 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lysine Clear all
Terminated Phase 2 Interventional Results available

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

NCT01808534
View directory record Official record
Conditions
Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Malignant Extragonadal Germ Cell Tumor, Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Ovarian Germ Cell Tumor
Interventions
palifosfamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 22, 2026, 2:04 AM EDT
Not listed Not applicable Interventional

Effect of an Amino-Acid-Based Blend on Human Growth Hormone (hGH) and Fibromyalgia (FM) Symptoms

NCT04510181
View directory record Official record
Conditions
Fibromyalgia
Interventions
amino acid-based blend
Dietary Supplement
Lead sponsor
Pekarovics, Susan, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury

NCT02535949
View directory record Official record
Conditions
Hemorrhage, Shock, Wounds and Injuries
Interventions
Tranexamic Acid, Placebo
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

Aztreonam Lysine for Pseudomonas Infection Eradication Study

NCT01375049
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Results available

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

NCT04750473
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Computed Tomography, Fluciclovine F18, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 22, 2026, 2:04 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer

NCT04377152
View directory record Official record
Conditions
Prostate Cancer, Prostate, Prostate Adenocarcinoma
Interventions
68Gallium-PSMA-11, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 22, 2026, 2:04 AM EDT
Recruiting Phase 1 Interventional

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05597306
View directory record Official record
Conditions
Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Interventions
Bomedemstat, Venetoclax
Drug
Lead sponsor
Terrence J Bradley, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Early Phase 1 Interventional Results available

Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure

NCT03446651
View directory record Official record
Conditions
Heart Failure
Interventions
Lysine Chloride, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers

NCT00175084
View directory record Official record
Conditions
Hyperlipidemias, Metabolic Syndrome X, Cardiovascular Diseases
Interventions
Comparison of dietary protein amino acid profile
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 3 Interventional

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

NCT02940262
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
Radiation · Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
1,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer

NCT00421135
View directory record Official record
Conditions
Advanced Cancer
Interventions
ZIO-201
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Santa Monica, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Oct 22, 2026, 2:04 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571
View directory record Official record
Conditions
Acute Myeloid Leukemias
Interventions
Revumenib, Chemotherapy Regimen, HiDAC
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Goodyear, Arizona • Burbank, California • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)

NCT01469364
View directory record Official record
Conditions
Complication of Transplanted Lung
Interventions
Aztreonam Lysine for Inhalation (AZLI), Status Post Lung Transplant
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1A Study of the Safety of KSP/QRH Dimer

NCT03643068
View directory record Official record
Conditions
Healthy Adults
Interventions
KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg, KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg
Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 22, 2026, 2:04 AM EDT
Recruiting Phase 1 Interventional

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT05098210
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
Interventions
Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Ruxolitinib
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

NCT03803475
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled PSMA-11, Positron emission tomography-computed tomography (PET/CT), Positron emission tomography-magnetic resonance imaging (PET/MRI)
Drug · Device
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 22, 2026, 2:04 AM EDT
Completed No phase listed Observational

Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution

NCT01736839
View directory record Official record
Conditions
Cystic Fibrosis in Adults, Chronic Colonization With Pseudomonas Aeruginosa
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 22, 2026, 2:04 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

NCT06991738
View directory record Official record
Conditions
Thyroid Cancer
Interventions
68Ga-DOTA-TATE PET Scan, Amino acid infusions, 177Lu-DOTA-EB-TATE
Diagnostic Test · Other · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients

NCT02919111
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled PSMA-11 PET
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 22, 2026, 2:04 AM EDT
Not listed Phase 2Phase 3 Interventional

Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)

NCT03612869
View directory record Official record
Conditions
Mucopolysaccharidosis Type IIIA
Interventions
LYS-SAF302
Drug
Lead sponsor
LYSOGENE
Industry
Eligibility
6 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Orange, California • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

NCT05547386
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Acute Lysine Administration on α-aminoadipic Acid (Sub-study)

NCT03063476
View directory record Official record
Conditions
Healthy
Interventions
C-13 labeled Lysine, Normal saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 22, 2026, 2:04 AM EDT
Terminated Phase 1Phase 2 Interventional

A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis

NCT04273269
View directory record Official record
Conditions
GM1 Gangliosidosis
Interventions
LYS-GM101
Genetic
Lead sponsor
LYSOGENE
Industry
Eligibility
Up to 3 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

NCT04216134
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 22, 2026, 2:04 AM EDT